Antibiotic Development Pipeline and Strategies Analysed in New In-Demand Study by Biopharm Reports Available at MarketPublishers.com

Share Article

While antibiotics are effective for the major of infections, increasing resistance in some pathogens threatens to undermine the few remaining drugs that are still effective against them. New market research report "Antibiotic Resistance 2012: The Antibiotic Development Pipeline and Strategies to Combat Antibiotic Resistance" prepared by Biopharm Reports has been recently published by Market Publishers Ltd.

marketpublishers.com

Market Publishers Ltd

While antibiotics are effective for the major of infections, increasing resistance in some pathogens threatens to undermine the few remaining drugs that are still effective against them. In the last decade, the capacity to target pathogens has been undermined by a lack of innovation, which has seen a 60% fall in the numbers of new approvals and few novel molecules. However, this trend is changing.

New market research report "Antibiotic Resistance 2012: The Antibiotic Development Pipeline and Strategies to Combat Antibiotic Resistance" prepared by Biopharm Reports has been recently published by Market Publishers Ltd.

Report Details:

Title: Antibiotic Resistance 2012: The Antibiotic Development Pipeline and Strategies to Combat Antibiotic Resistance
Published: January, 2012
Pages: 120
Price: US$ 2,300
http://marketpublishers.com/report/medicine_pharmaceuticals_biotechnology/drugs_biotechnology/pantibiotic_resistance_2012_antibiotic_development_pipeline_n_strategies_to_combat_antibiotic_resistance.html

The report features a comprehensive overview of global antibiotic resistance, the antibiotics pipeline and new strategies to target resistance mechanisms. It identifies 109 antibiotics in the development pipeline, approximately 70% of which are in early development. Moreover it examines 209 marketed antibiotics for the treatment of bacterial and fungal infections.

Report Contents:

EXECUTIVE SUMMARY

CHAPTER 1 INTRODUCTION

1.1 Antibiotic Resistance
1.2 Resistance Mechanisms
1.3 The Resistome
1.4 Pathogenomics
1.5 Strategies and Targets
1.6 The Cost of Antibiotic Resistance
1.7 Global Surveillance
1.8 This Report

CHAPTER 2 ANTIBIOTIC RESISTANCE, GLOBAL TRENDS

2.1 Antibiotic Resistance
2.2 Europe
2.2.1 Carbapenem-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa (2005 to 2010)
2.2.2 Escherichia coli
2.2.3 Streptococcus pneumoniae
2.2.4 Staphylococcus aureus
2.2.5 Enterococcus faecalis
2.2.6 Klebsiella pneumoniae
2.2.7 Pseudomonas aeruginosa
2.3 Other Countries
2.4 China
2.5 USA
2.6 Kuwait
2.7 Discussion

CHAPTER 3 MARKETED ANTIBIOTICS

3.1 Marketed Antibiotics
3.2 Mechanisms
3.3 Companies
3.4 Sulphonamides
3.5 Beta Lactams (penicillins, cephalosporins, carbapenems, monobactams)
3.6 Aminoglycosides
3.7 Tetracyclines
3.8 Quinolones/Fluoroquinolones
3.9 Macrolides
3.10 Combinations
3.11 Folate antagonists
3.12 Mycobacterials
3.13 Glycopeptides
3.14 Others
3.15 Discussion

CHAPTER 4 PIPELINE ANTIBIOTICS

4.1 Pipeline Antibiotics
4.2 Companies
4.3 Phase 3
4.4 Phase 2
4.5 Phase 1
4.6 Preclinical
4.7 Discussion

CHAPTER 5 DISCUSSION

5.1 Background
5.2 Mechanisms
5.3 Multiple Activities
5.4 Marketed Antibiotics
5.5 Antibiotics Pipeline
5.6 Circumventing Resistance
5.7 Resistance Mutations
5.8 Virulence
5.9 Conclusions

REFERENCES

TABLES
FIGURES

More new market research reports by the publisher can be found at Biopharm Reports page.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Tanya Rezler
Visit website